TL;DR: Curaleaf Holdings (OTC: CURLF) trades at $9.46 ahead of its August 5, 2026 Q2 earnings release — the most anticipated reporting date in the cannabis MSO calendar this quarter. The largest US multi-state operator by revenue enters the earnings window generating positive free cash flow of $82.49M (TTM) while analyst consensus targets $15.00 per share, implying 58.6% upside from current levels.
Market Analysis
Shares gained 1.72% to $9.46 in midday trading Friday, extending a 1-year return of 158.47% that substantially outpaces the broader equity market. The stock trades in the middle of its 52-week range of $2.83–$15.15, suggesting neither a momentum peak nor capitulation. Year-to-date performance stands at +22.70%, which lags the 1-year trajectory and signals mid-year consolidation as the market awaits fundamental confirmation from the August reporting window.
At a $2.51 billion market capitalization, Curaleaf remains the largest cannabis company by market value on the US OTC markets. Enterprise value of $3.24 billion reflects total debt obligations, with a debt-to-equity ratio of 114.54% — elevated relative to peers but manageable given trailing 12-month levered free cash flow of $82.49 million. Profitability remains elusive on a net income basis (EPS TTM: -$0.42), but the positive FCF trajectory demonstrates operational discipline at scale.
Revenue for the trailing twelve months stands at $1.29 billion — the only cannabis MSO approaching $1.3B in annual revenue. The stock trades at 1.96x Price/Sales and an enterprise value/revenue multiple of 2.52x, with EV/EBITDA of 14.31x on a trailing basis. These multiples price in meaningful operational improvement relative to smaller-cap MSO peers trading at steeper discounts.
Q2 2026 Earnings Preview — August 5
The August 5 reporting date positions Curaleaf as one of the first major US MSOs to report Q2 results, setting the tone for an earnings window extending through mid-August. Key metrics for investors to monitor include:
- Revenue trajectory: Whether sequential Q2 revenue improves on Q1 2026 levels, particularly across Florida and mature adult-use states where Curaleaf maintains significant retail footprints.
- EBITDA margin: Wholesale pricing compression has weighed on MSO margins sector-wide; a stabilization signal would be constructive for the sector multiple.
- Debt management: With $3.24B enterprise value against $2.51B market cap, the spread represents net debt overhang. Balance sheet progress — paydowns, refinancing, or term extensions — will receive close analyst scrutiny.
- Free cash flow guidance: Trailing levered FCF of $82.49M is the clearest evidence of operational discipline. Sustained or improving FCF generation validates the $15.00 analyst consensus target.
Regulatory and Market Context
The federal cannabis regulatory environment continues evolving heading into Q3 2026. Schedule III reclassification proceedings remain in motion, with the DEA administrative law process ongoing. A favorable Schedule III outcome would eliminate 280E tax treatment for licensed cannabis companies — a direct earnings catalyst estimated to add hundreds of millions to sector-wide net income. Curaleaf, as the largest US operator by revenue, stands among the most significant potential beneficiaries of 280E relief.
State-level dynamics remain mixed. Florida represents a core Curaleaf market where the path to adult-use expansion has encountered legislative uncertainty following the 2024 ballot outcome. Meanwhile, mature markets in New York, New Jersey, and Pennsylvania continue generating incremental licensed store openings and revenue diversification. Management commentary on state-by-state dynamics will be closely parsed during the Q2 earnings call.
Conclusion
At $9.46 with an August 5 earnings catalyst and a $15.00 analyst consensus target, Curaleaf presents a defined risk/reward inflection point for cannabis sector investors. The bull case rests on sustained revenue growth, FCF generation, and eventual 280E relief under Schedule III. The bear case centers on leverage, competitive pricing pressure, and continued regulatory uncertainty at the federal level. With the sector’s most liquid OTC name reporting in five trading days, positioning decisions will likely solidify before earnings open — making Friday’s session an active risk assessment window. Monitor live CURLF price action and sector-wide performance on the cannabis stock tracker.